Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.46 |
| ▸ | HTR1A | P08908 | 6/20 | 0.44 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | AQP1 | P29972 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 5/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4596981 | 0.91 | PARP1 (0.48) | PARP1HTR1AMAOAMAOBAQP1 | |
| SCHEMBL4595292 | 0.85 | AQP1 (0.44) | PARP1HTR1AMAOAMAOBAQP1 | |
| SCHEMBL4597590 | 0.85 | HTR1A (0.46) | PARP1HTR1AMAOAMAOBCNR1 | |
| SCHEMBL4712948 | 0.82 | BRD4 (0.44) | PARP1HTR1AMAOAMAOBAQP1 | |
| SCHEMBL4596982 | 0.82 | AQP1 (0.50) | PARP1HTR1AMAOAMAOBAQP1 | |
| SCHEMBL4595494 | 0.82 | AQP1 (0.36) | HTR1AAQP1HTR7 | |
| SCHEMBL4649844 | 0.81 | PARP1 (0.48) | PARP1HTR1AMAOAMAOBCNR1 | |
| SCHEMBL4596565 | 0.80 | PARP1 (0.53) | PARP1HTR1AMAOAMAOBBRD4 | |
| SCHEMBL4595480 | 0.78 | PARP1 (0.43) | PARP1HTR1AMAOAMAOBAQP1 | |
| SCHEMBL4225662 | 0.78 | AQP1 (0.44) | HTR1AAQP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1998764-A2 | METHODS FOR TREATING COGNITIVE AND OTHER DISORDERS | Wyeth a Corporation of the State of Delaware (US) | 2008-12-10 | — | — | EP | claimed |
| WO-2007112065-A2 | METHODS FOR TREATING COGNITIVE AND OTHER DISORDERS | WYETH (US) | 2007-10-04 | — | — | WO | claimed |
| JP-2007509174-A | — | — | 2007-04-12 | — | — | JP | claimed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | claimed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | claimed |
| EP-1898895-A2 | TREATMENT OF DRUG ABUSE | Wyeth (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1874750-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth Incoporated (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006116148-A2 | (7-ARLYSUBSTITUTED 2, 3-DIHYDR0-1-BENZ0FURAN-2-YL) ALKYLAMINES IN THE TREATMENT' OF SUBSTANCE ABUSE | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | disclosed |